Agios Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: AGIO · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1439222
| Field | Detail |
|---|---|
| Company | Agios Pharmaceuticals, Inc. (AGIO) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Agios Pharma filed an 8-K about a shareholder vote. Details TBD.
AI Summary
On June 20, 2024, Agios Pharmaceuticals, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not contain specific details about the proposals or the outcome of any vote, but indicates that a shareholder vote is scheduled or has occurred.
Why It Matters
This filing signals that Agios Pharmaceuticals is engaging in corporate governance processes requiring shareholder approval, which could impact the company's direction or shareholder rights.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial information or significant operational changes.
Key Players & Entities
- Agios Pharmaceuticals, Inc. (company) — Registrant
- June 20, 2024 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Agios Pharmaceuticals' security holders?
The filing states that matters were submitted to a vote of security holders, but does not specify what those matters were.
When did the event related to the shareholder vote occur or is it scheduled for?
The filing indicates the date of the earliest event reported is June 20, 2024.
What is the principal executive office address for Agios Pharmaceuticals?
The principal executive offices are located at 88 Sidney Street, Cambridge, MA 02139.
What is the IRS Employer Identification Number for Agios Pharmaceuticals?
The IRS Employer Identification Number is 26-0662915.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-06-20 17:06:01
Key Financial Figures
- $0.001 — ich registered Common Stock, Par Value $0.001 per share AGIO Nasdaq Global Select
Filing Documents
- d645924d8k.htm (8-K) — 34KB
- 0001193125-24-164555.txt ( ) — 148KB
- agio-20240620.xsd (EX-101.SCH) — 2KB
- agio-20240620_lab.xml (EX-101.LAB) — 17KB
- agio-20240620_pre.xml (EX-101.PRE) — 11KB
- d645924d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGIOS PHARMACEUTICALS, INC. Date: June 20, 2024 By: /s/ Brian Goff Brian Goff Chief Executive Officer